These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 21925881)

  • 1. Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.
    Wilson LJ; Wang B; Yang SM; Scannevin RH; Burke SL; Karnachi P; Rhodes KJ; Murray WV
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6485-90. PubMed ID: 21925881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.
    Zhang YM; Fan X; Xiang B; Chakravarty D; Scannevin R; Burke S; Karnachi P; Rhodes K; Jackson P
    Bioorg Med Chem Lett; 2006 Jun; 16(12):3096-100. PubMed ID: 16632358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. QSAR analysis of some 5-amino-2-mercapto-1,3,4-thiadiazole based inhibitors of matrix metalloproteinases and bacterial collagenase.
    Jamloki A; Karthikeyan C; Hari Narayana Moorthy NS; Trivedi P
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3847-54. PubMed ID: 16682189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.
    Reiter LA; Robinson RP; McClure KF; Jones CS; Reese MR; Mitchell PG; Otterness IG; Bliven ML; Liras J; Cortina SR; Donahue KM; Eskra JD; Griffiths RJ; Lame ME; Lopez-Anaya A; Martinelli GJ; McGahee SM; Yocum SA; Lopresti-Morrow LL; Tobiassen LM; Vaughn-Bowser ML
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3389-95. PubMed ID: 15177439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.
    Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Chen L; Dunaway CM; Gu F; Mieling GE
    J Med Chem; 1999 Jan; 42(1):87-94. PubMed ID: 9888835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor.
    Maquoi E; Sounni NE; Devy L; Olivier F; Frankenne F; Krell HW; Grams F; Foidart JM; Noël A
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4038-47. PubMed ID: 15217936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel matrix metalloproteinase inhibitors derived from quinoxalinone scaffold (Part I).
    Li Y; Zhang J; Xu W; Zhu H; Li X
    Bioorg Med Chem; 2010 Feb; 18(4):1516-25. PubMed ID: 20097082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-capillary screening of matrix metalloproteinase inhibitors by electrophoretically mediated microanalysis with fluorescence detection.
    Hai X; Wang X; El-Attug M; Adams E; Hoogmartens J; Van Schepdael A
    Anal Chem; 2011 Jan; 83(1):425-30. PubMed ID: 21142123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13.
    Monovich LG; Tommasi RA; Fujimoto RA; Blancuzzi V; Clark K; Cornell WD; Doti R; Doughty J; Fang J; Farley D; Fitt J; Ganu V; Goldberg R; Goldstein R; Lavoie S; Kulathila R; Macchia W; Parker DT; Melton R; O'Byrne E; Pastor G; Pellas T; Quadros E; Reel N; Roland DM; Sakane Y; Singh H; Skiles J; Somers J; Toscano K; Wigg A; Zhou S; Zhu L; Shieh WC; Xue S; McQuire LW
    J Med Chem; 2009 Jun; 52(11):3523-38. PubMed ID: 19422229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.
    Le Diguarher T; Chollet AM; Bertrand M; Hennig P; Raimbaud E; Sabatini M; Guilbaud N; Pierré A; Tucker GC; Casara P
    J Med Chem; 2003 Aug; 46(18):3840-52. PubMed ID: 12930146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.
    Breuer E; Salomon CJ; Katz Y; Chen W; Lu S; Röschenthaler GV; Hadar R; Reich R
    J Med Chem; 2004 May; 47(11):2826-32. PubMed ID: 15139760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sultam hydroxamates as novel matrix metalloproteinase inhibitors.
    Cherney RJ; Mo R; Meyer DT; Hardman KD; Liu RQ; Covington MB; Qian M; Wasserman ZR; Christ DD; Trzaskos JM; Newton RC; Decicco CP
    J Med Chem; 2004 Jun; 47(12):2981-3. PubMed ID: 15163180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of an orally active matrix metalloproteinase inhibitor.
    Yamamoto S; Nakatani S; Ikura M; Sugiura T; Nishita Y; Itadani S; Ogawa K; Ohno H; Takahashi K; Nakai H; Toda M
    Bioorg Med Chem; 2006 Sep; 14(18):6383-403. PubMed ID: 16765051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyrimidine-2,4,6-Triones: a new effective and selective class of matrix metalloproteinase inhibitors.
    Grams F; Brandstetter H; D'Alò S; Geppert D; Krell HW; Leinert H; Livi V; Menta E; Oliva A; Zimmermann G; Gram F; Brandstetter H; D'Alò S; Geppert D; Krell HW; Leinert H; Livi VMenta E; Oliva A; Zimmermann G
    Biol Chem; 2001 Aug; 382(8):1277-85. PubMed ID: 11592410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, SAR, and biological evaluation of alpha-sulfonylphosphonic acids as selective matrix metalloproteinase inhibitors.
    Rubino MT; Agamennone M; Campestre C; Fracchiolla G; Laghezza A; Loiodice F; Nuti E; Rossello A; Tortorella P
    ChemMedChem; 2009 Mar; 4(3):352-62. PubMed ID: 19204958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides.
    Tuccinardi T; Martinelli A; Nuti E; Carelli P; Balzano F; Uccello-Barretta G; Murphy G; Rossello A
    Bioorg Med Chem; 2006 Jun; 14(12):4260-76. PubMed ID: 16483784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: a first round of lead optimization.
    La Pietra V; Marinelli L; Cosconati S; Di Leva FS; Nuti E; Santamaria S; Pugliesi I; Morelli M; Casalini F; Rossello A; La Motta C; Taliani S; Visse R; Nagase H; da Settimo F; Novellino E
    Eur J Med Chem; 2012 Jan; 47(1):143-52. PubMed ID: 22088955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zinc-binding groups.
    Puerta DT; Lewis JA; Cohen SM
    J Am Chem Soc; 2004 Jul; 126(27):8388-9. PubMed ID: 15237990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.
    Fray MJ; Dickinson RP; Huggins JP; Occleston NL
    J Med Chem; 2003 Jul; 46(16):3514-25. PubMed ID: 12877590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel 3-galloylamido-N'-substituted-2,6-piperidinedione-N-acetamide peptidomimetics as metalloproteinase inhibitors.
    Li Q; Fang H; Xu W
    Bioorg Med Chem Lett; 2007 May; 17(10):2935-8. PubMed ID: 17433673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.